Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513331 | 0.69 | METAP2 (0.57) | METAP2FGFR1MAPTKDM4EALDH1A1 | |
| SCHEMBL19304131 | 0.69 | METAP2 (0.47) | METAP2FGFR1MAPTKDM4E | |
| SCHEMBL19115364 | 0.68 | MAPT (0.51) | FGFR1MAPTKDM4EALDH1A1TGFBR1 | |
| SCHEMBL13267320 | 0.67 | METAP2 (0.60) | METAP2FGFR1MAPTKDM4EALDH1A1 | |
| SCHEMBL84508 | 0.66 | METAP2 (0.68) | METAP2FGFR1MAPTKDM4EALDH1A1 | |
| SCHEMBL17030767 | 0.65 | MAPT (0.58) | METAP2FGFR1MAPTKDM4EALDH1A1 | |
| SCHEMBL21363598 | 0.63 | METAP2 (0.43) | METAP2FGFR1MAPTKDM4EIDH1 | |
| SCHEMBL21891466 | 0.63 | MAPT (0.36) | MAPTALDH1A1 | |
| SCHEMBL20272864 | 0.62 | METAP2 (0.50) | METAP2FGFR1MAPTKDM4EALDH1A1 | |
| SCHEMBL13930937 | 0.61 | METAP2 (0.60) | METAP2FGFR1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | METAP2 2901/4885FGFR1 1538/4885MAPT 761/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | METAP2 2875/4885FGFR1 1967/4885MAPT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.